UOC
OCUL icon

UBS O'Connor’s Ocular Therapeutix OCUL Stock Holding History

UBS O'Connor’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-120,000
Closed -$153K – 405
2025
Q2 		$153K Hold
120,000
– – ﹤0.01% 302
2025
Q1 		$123K Buy
+120,000
New +$922K ﹤0.01% 260
2024
Q2 		– Sell
-50,000
Closed -$8.75K – 612
2024
Q1 		$8.75K Buy
+50,000
New +$355K ﹤0.01% 492

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

UBS O'Connor's OCUL Position: Q3 2025 in Review

UBS O'Connor sold out of Ocular Therapeutix (OCUL) in Q3 2025, closing a stake of 210,205 shares — an estimated $1.95M sold.

UBS O'Connor first reported a position in OCUL in Q1 2022 and held it in 14 quarters. The position peaked at $2.31M in Q4 2024. 216 funds tracked by Wall St. Rank hold OCUL as of Q3 2025.

  • UBS O'Connor reported no remaining Ocular Therapeutix position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 210,205 Ocular Therapeutix shares in Q3 2025, an estimated $1.95M.
  • UBS O'Connor first reported a position in Ocular Therapeutix in Q1 2022 and held it in 14 quarters.
  • UBS O'Connor's Ocular Therapeutix position peaked at $2.31M in Q4 2024.
  • 216 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.